echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Heji Pharmaceutical's first ITK inhibitor application IND accepted in the clinical stage in the world

    Heji Pharmaceutical's first ITK inhibitor application IND accepted in the clinical stage in the world

    • Last Update: 2021-08-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On August 17, Heji Pharmaceuticals revealed that its first clinical trial application for the oral ITK inhibitor CPI-818, which entered the clinical development stage, was accepted by the NMPA Drug Approval Center, and it was intended to be used for relapsed/refractory T cells.


    CPI-818 can strongly inhibit ITK kinase and is highly selective without affecting normal T cell proliferation and immune response


    In the first human clinical trials conducted in the United States, South Korea, and Australia, CPI-818 has shown definite efficacy and good safety and tolerability


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.